Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Total Current Liabilities
All obligations due within one year.
Prime Medicine, Inc.NASDAQ: PRME
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 5.8% from a year ago
Total current liabilities stood at $36.29M at the end of Q1 FY2026, up 5.8% from a year earlier and down 3.1% from the prior quarter. Over 3 fiscal years it compounded at +11.9% a year.
Context
- Total current liabilities amounted to 12.3% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +5.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 37.45M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- -10.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.45M | -1.4% |
| FY2024 | 2024-12-31 | 37.96M | -32.7% |
| FY2023 | 2023-12-31 | 56.42M | +111.2% |
| FY2022 | 2022-12-31 | 26.71M | -53.9% |
| FY2021 | 2021-12-31 | 57.98M | — |
Total Current Liabilities vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's Mar 2026 total current liabilities of $36.29M is the 5th highest of the 7 companies compared; the peer median is $58.11M.
- Its year-over-year change of +5.8% is the 3rd highest of 7, against a peer median of -31.5%.
- Total current liabilities amounts to 12.3% of total assets for PRME, versus a peer median of 8.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $140.96M | +18.5% | +7.2% | 5.5% | |
| Jun 2026 | $80.88M | -53.6% | -24.3% | 5.8% | |
| Mar 2026 | $76.45M | -32.1% | -6.4% | 10.1% | |
| Mar 2026 | $39.78M | -45.6% | -8.4% | 26.6% | |
| Mar 2026 | $36.29M | +5.8% | +11.9% | 12.3% | |
| Mar 2026 | $19.67M | -31.0% | -3.3% | 13.2% | |
| Mar 2026 | $10.19M | +23.7% | +6.6% | 4.4% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | $58.11M | -31.5% | -4.8% | 8.0% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.42M | 187.62M | 41.57M | 182.48M | 63.03M |
| Short-term Investments | 84.2M | 106.3M | 80.09M | 7.97M | 114.65M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 246K | 2.25M | 14.67M | 3.61M |
| Total Current Assets | 270.58M | 296.62M | 142.98M | 211.89M | 181.29M |
| Property, Plant & Equipment (Net) | 15.68M | 48.55M | 36.6M | 71.56M | 146.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15.6M | 15.14M | 14.28M | 14.06M | 14.69M |
| Total Non-current Assets | 31.28M | 63.7M | 50.88M | 85.62M | 161.44M |
| Total Assets | 301.86M | 360.31M | 193.85M | 297.51M | 342.73M |
| Account Payables | 1.44M | 4.33M | 19.54M | 11.35M | 8.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 7.09M | 7.82M |
| Other Current Liabilities | 14.66M | 6.98M | 10.91M | 6.93M | 9.04M |
| Total Current Liabilities | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 108.29M |
| Deferred Tax Liabilities | 1.24M | 279K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 63.22M | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 6M | 76.13M |
| Total Non-current Liabilities | 4.31M | 17.33M | 4.36M | 106.4M | 184.42M |
| Total Liabilities | 62.3M | 44.04M | 60.78M | 144.36M | 221.87M |
| Common Stock | 1K | 2K | 2K | 2K | 2K |
| Retained Earnings | (171.38M) | (293.2M) | (491.33M) | (687.21M) | (888.35M) |
| Accumulated OCI | (27K) | (384K) | (15K) | 1K | 82K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 239.56M | 316.27M | 133.07M | 153.15M | 120.87M |
| Total Debt | 10.41M | 28.75M | 13.63M | 40.79M | 116.43M |
| Net Debt | (175.01M) | (158.88M) | (27.94M) | (141.68M) | 53.4M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.